Prednisona e meloxicam no tratamento de ratos submetidos ao trauma agudo da medula espinhal

Abstract

RESUMO O objetivo deste estudo foi investigar o efeito da prednisona e do meloxicam na terapia de ratos submetidos ao modelo experimental de trauma agudo da medula espinhal, induzida pelo cateter de Fogarty 2Fr, mediante a avaliação dos parâmetros de estresse oxidativo, dos testes neurológicos e do

Clinical Evaluation of the Effect of Methylprednisolone Sodium Succinate and Meloxicam in Experimental Acute Spinal Cord Injury

“…They showed that meloxicam and MPSS could exhibit antioxidant effects and neuroprotective action, but the necrosis and Wallerian degeneration did not stop in rats that underwent acute SCI compared to the control group. Also, they reported that meloxicam had an antioxidant activity that was more prolonged than the group treated with MPSS, mainly due to decreased catalase activity (Aiello et al, 2015). Similar to our study, they administered meloxicam and MPSS one hour after the spinal cord injury.…”

“…Similar to our study, in the report of Hakan, locomotion scores were better in the meloxicamtreated group, probably due to repeated prescriptions, but it was not statistically significant compared to the control group (Hakan et al, 2010). Aiello et al (2015) evaluated the effects of prednisone and meloxicam in treating rats that underwent acute SCI. MPSS and meloxicam treatment groups received MPSS and meloxicam with a dosage of 2 mg/kg, IP, every 24 h for 72 h. The beginning of administering two drugs was 60 minutes after the surgical procedure in all the groups.…”

“…In our study, and based on other studies (Bracken et al,1992), it has been shown that MPSS should be administered at 30 mg/kg within one hour after injury to be effective. The reduced dose of methylprednisolone (2 mg/kg) in the study of Aiello et al (2015) is a clear reason for the reduced effect of methylprednisolone compared to meloxicam. Also, Hayta & Elden (2018), in a study, stated that the administration of different NSAIDs in animal models of SCI is not significantly associated with an improvement in locomotor function (Hayta & Elden, 2018).…”